⭐

Novartis AG

NOVN.SWDividend Aristocrat • 27yrs
Healthcare · Drug Manufacturers - General🇨🇭 Switzerland
CHF 131.48
Dividend Yield2.78%
Annual DividendCHF 3.70
Ex-Dividend DateMar 10, 2026
Market CapCHF 248.32B
77/ 100
Financial Health
Healthy
⚠ High payout ratio (87%)Conservative leverage (D/E 1.3x)Strong ROE (24%)27-year Aristocrat

Automated dividend-safety read-out from payout, leverage, yield, profitability and track record. See the Financials tab for the full per-statement Financial Investigation. Educational only — not investment advice.

At a glance

Novartis AG (NOVN.SW) operates in the Drug Manufacturers - General industry and is based in Switzerland. It pays a quarterly dividend of CHF 3.70 a year, a yield of 2.78% at the current price of CHF 131.48. Novartis has raised its dividend for 27 consecutive years, which makes it a Dividend Aristocrat. Over the last five years the dividend has grown by an average of 3.5% a year. It paid out 87% of its earnings as dividends. 22 analysts cover it; their average 12-month price target of CHF 129.74 is 1.3% below the current price.

Written automatically from the figures on this page, as of Nov 19, 2026. Facts only, not a recommendation.

Price History
Dividend payment dates
Analyst Consensus
Hold
Bullish sentiment
41% of 22 analysts bullish
12-Month Price Target
CHF 129.74
-1.3% vs current price

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.

Business description from Yahoo Finance. Verify details in the company's own annual report.

Key Metrics

Valuation

P/E Ratio
31.5
P/B Ratio
8.09
EV/EBITDA
12.0
Beta
0.45
vs S&P 500
52W High
CHF 137.00
52W Low
CHF 99.45

Profitability

Gross Margin
75.21%
Operating Margin
33.98%
Net Margin
17.49%
ROE
24.33%
Free Cash Flow
CHF 11.27B

Financial Health

Debt / Equity
1.29x
total debt ÷ equity; lower is safer
Current Ratio
0.88
>1 healthy
Quick Ratio
0.58
>1 healthy
Employees
75,267
HQ
Basel, Switzerland
Data: Yahoo Finance (yfinance)|Updated: Nov 19, 2026 02:03

Data provided by Yahoo Finance via yfinance. Updated daily. Not investment advice.

Legal Disclaimer

This website is not a financial advisor, investment advisor, or financial services provider. We do not offer, recommend, or imply any investment advice of any kind. We do not receive compensation, commissions, or any other benefit from any company, fund, financial product, or third party featured on this site. No content on this website constitutes a recommendation or solicitation to buy, sell, or hold any security or financial instrument.

All financial analysis, ratios, and written commentary are provided for educational and informational purposes only. The Financial Analysis and Financial Investigation sections reflect automated computations applied to publicly available financial data — they do not represent the opinion of a licensed financial professional. Always conduct your own independent research and consult a qualified, regulated financial adviser before making any investment decision. Past performance of dividends, prices, or earnings is not a guarantee of future results.

Data Sources: Yahoo Finance via yfinance (real-time prices, dividend history, financial statements, analyst ratings and price targets) · S&P 500 Dividend Aristocrats Index (official constituent list) · Dividend Kings public records (companies with 50+ years of consecutive dividend increases) · SEC EDGAR company filings (10-K annual reports — primary source for all financial statement data). Data is fetched automatically each day and may be delayed up to 24 hours. All figures are in USD unless otherwise stated.